ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1444	National Cancer Institute	Html	en	Adult Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.	characteristic genetic abnormalities 0.39234 Adult Acute Myeloid 0.42781 acute myelogenous leukemia 0.488829 acute biphenotypic leukemia 0.454638 Acute myeloblastic leukemia 0.474183 acute erythroblastic leukemia 0.447971 monoblastic leukemia antigens 0.403407 transient leukemia 0.398296 Leukemia Group 0.421425 acute eosinophilic leukemia 0.464145 acute leukemias 0.416535 biphenotypic acute leukemia 0.461147 acute monocytic leukaemia 0.396733 chronic myeloid leukemia 0.484726 chronic myelomonocytic leukemia 0.40262 AML 0.598074 World Health Organization 0.418965 Health Organization Classification 0.417813 acute monocytic leukemia 0.541741 minimally differentiated AML 0.404409 acute erythroid leukemias. 0.391545 acute leukemia patients 0.46612 blast percentage 0.399782 myelodysplastic syndromes 0.404558 et al. 0.486443	lineage acute leukemia 0.472137 acute megakaryoblastic leukemia 0.570037 acute biphenotypic leukaemia 0.396849 internal tandem duplication 0.391126 Br J Haematol 0.407064 acute monoblastic leukemia 0.552455 adult megakaryoblastic leukemia 0.392499 acute myeloid leukemia 0.936356 acute myeloid leukaemia 0.463297 acute myelomonocytic leukemia 0.509496 genetic abnormalities 0.393333 acute megakaryocytic leukemia 0.467082 differential diagnosis 0.419864 cases 0.405688 Abstract 0.458712 pure erythroid leukemia 0.448165 cytochemical features 0.408002 acute erythroid leukemia 0.471063 bone marrow 0.469209 acute erythroid leukemias 0.400236 acute promyelocytic leukemia 0.615165 acute nonlymphocytic leukemia 0.489262 acute lymphoblastic leukemia 0.489649 acute leukemia 0.565771	CLICK HERE
1539	National Cancer Institute	Html	en	Adult Primary Liver Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult primary liver cancer.	Adult liver cancer 0.3229 bile duct cancer 0.289957 cancer spreads 0.268265 body 0.335412 healthy liver tissue 0.301199 PDQ cancer information 0.323551 clinical trial search 0.281007 clinical trials 0.55174 cancer information summary 0.30136 adult primary liver 0.896168 clinical trial 0.389615 liver disease 0.276306 detailed pictures 0.294233 healthy donated liver 0.285489 treatment clinical trial 0.264079 body radiation therapy 0.304178 NCI PDQ cancer 0.273742 malignant tumor cells 0.27026 Duct Cancer Treatment 0.289551 radiation therapy 0.397919 Childhood Liver Cancer 0.337182 entire liver 0.272876 general cancer information 0.265929 treatment 0.426881 liver injury 0.286661	hepatic portal vein 0.283724 Clinic Liver Cancer 0.322316 metastatic liver cancer 0.323102 nearby healthy tissue 0.265169 NCI-supported cancer 0.264234 cancer cells 0.36535 hepatic artery 0.317753 primary liver cancer 0.97153 Cancer Information Service 0.266321 specific cancer cells 0.265527 Liver Cancer Treatment 0.368965 patient 0.265351 treatment clinical trials 0.285012 National Cancer Institute 0.332241 stereotactic body radiation 0.30319 liver transplant 0.296023 new treatment 0.282659 external radiation therapy 0.294036 blood 0.29169 PDQ summary 0.268144 cancer clinical trials 0.30738 tumor 0.3047 cancer information summaries 0.264877 comprehensive cancer information 0.264661	CLICK HERE
1634	National Cancer Institute	Html	en	Hydrazine Sulfate (PDQ®)–Patient Version	Expert-reviewed information summary about the use of hydrazine sulfate as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	randomized controlled trials 0.450078 treatment 0.522727 cancer treatment 0.475015 cancer prevention 0.44047 Complementary Therapies Editorial 0.452982 United States 0.440744 Drug Administration 0.454034 Cancer Information Specialist 0.44699 cancer cells 0.451523 Cancer Information Service 0.478296 hydrazine compounds 0.44033 PDQ cancer information 0.502287 Cancer Complementary 0.451114 body weight 0.443552 hydrazine sulfate treatment 0.519798 preclinical studies 0.453016 CAM therapies 0.439277 treatment clinical trials 0.44455 National Cancer Institute 0.557582 studies 0.47528 clinical trials 0.59962 colon cancer patients 0.451298 alternative medicine 0.474569 conventional treatment 0.441057	cancer information summary 0.479257 alternative cancer therapies 0.448575 Federal Trade Commission 0.442333 National Institutes 0.438958 clinical trial 0.445969 lung cancer patients 0.451382 CAM cancer research 0.443791 nutritional status 0.439129 breast cancer prevention 0.438548 advanced cancer 0.438703 patients 0.50459 cancer patients 0.480463 Cancer Care page 0.43981 health 0.440064 hydrazine sulfate 0.914395 PDQ summary 0.439248 NCI PDQ cancer 0.463099 cancer information database 0.449512 effects 0.440229 alternative therapies 0.459489 cancer information summaries 0.449727 Therapies Editorial Board 0.445847 randomized clinical trials 0.444095	CLICK HERE
1660	National Cancer Institute	Html	en	Liver (Hepatocellular) Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer.	PDQ Screening 0.551346 hepatocellular) cancer: 0.719756 cancer treatment 0.490974 cancer screening methods 0.577774 United States 0.488028 ongoing clinical trials 0.569331 routine screening tests 0.542104 Abnormal screening results 0.526706 following PDQ summaries 0.569947 Cancer Information Service 0.537158 PDQ cancer information 0.763376 false-negative test result 0.487695 widely used tumor 0.492628 common cancer 0.497307 Prevention Editorial Board 0.554017 treatment clinical trials 0.497409 National Cancer Institute 0.639479 clinical trials 0.758209 early detection 0.490925 PDQ documents 0.509492 test result 0.528806 cancer information summary 0.632034 new treatment 0.500882 breast cancer prevention 0.517023	diagnostic tests 0.505464 test results 0.489974 Cancer screening trials 0.585626 tumor markers 0.491268 NCI website 0.503158 false-positive test result 0.487287 cancer patients 0.48575 Cancer Care page 0.521215 PDQ database 0.515283 latest published information 0.502276 specific tumor marker 0.485952 NCI’s PDQ 0.524006 risk factor 0.495527 PDQ summary 0.551372 liver biopsy 0.551147 cancer symptoms 0.506472 NCI PDQ cancer 0.600996 Chinese American men 0.489845 tests 0.559642 cancer information summaries 0.546479 comprehensive cancer information 0.546147 cancer 0.936669 liver cancer 0.793964	CLICK HERE
1930	National Cancer Institute	Html	es	Tratamiento del cáncer de células de transición de pelvis renal y de uréter (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de células de transición de pelvis renal y de uréter.	PDQ Tratamiento 0.301965 siguientes procedimientos 0.300864 presente sección 0.300329 tinte circula 0.300646 siguientes aspectos 0.30066 Physician Data Query 0.300636 estadio i 0.300593 estadio ii 0.300585 túbulos renales 0.300794 rayos x 0.301624 sistema urinario masculino 0.301197	vejiga almacena 0.301076 ondas sonoras 0.300597 National Cancer Institute 0.30009 células renales 0.304024 siguientes riesgos 0.300073 pelvis renal 0.995929 materiales plásticos 0.300686 siguientes pruebas 0.30061 siguientes estadios 0.301441 Instituto Nacional 0.300663	CLICK HERE
2004	National Cancer Institute	Html	es	Familiares a cargo de pacientes de cáncer (PDQ®)–Versión para pacientes	Sumario informativo revisado por expertos acerca de los desafíos que enfrentan los familiares a cargo de los pacientes con cáncer. Este resumen se centra en las funciones típicas y las inquietudes de las personas a cargo del paciente y en las intervenciones útiles para esas personas.	etapa final 0.997354 medicamento ayuda 0.410369 antecedentes médicos 0.415405 duro trabajo 0.413212 siguientes aspectos 0.407494 siguientes tareas 0.552864 PDQ Familiares 0.404616 siguientes estrategias 0.423753 largo plazo 0.416925 orientación ayuda 0.4088 siguientes riesgos 0.402546 paciente ayuda 0.564496 comunicación ayuda 0.423969 Instituto Nacional 0.414173 habilidades específicas mejora 0.409415	paciente colabora 0.698305 bienestar espiritual ayuda 0.42734 Physician Data Query 0.413876 siguientes recompensas 0.416674 menudo personas 0.450696 Medical Leave Act 0.420162 escaso apoyo 0.411288 Caregiver Cancer Education 0.408929 numerosas tareas 0.412096 PDQ Comunicación 0.408163 terminales ayuda 0.406412 largo tiempo 0.456845 importantes decisiones 0.42081 viejos problemas 0.406452	CLICK HERE
2117	National Cancer Institute	Html	es	Brotes de cáncer	Hoja informativa que describe lo que es un brote de cáncer, el proceso para notificar e investigar brotes sospechosos y los retos en la investigación de brotes sospechosos.	Seguridad Ocupacional 0.284426 posibles carcinógenos 0.307688 múltiples tipos 0.294654 Centro Nacional 0.429489 Health Consultations.  0.283346 cabo programas 0.28293 Sustancias Tóxicas 0.544168 Public Health Assessments 0.353028 ambiente causantes 0.320442	Salud Ambiental 0.29888 Estados Unidos 0.297229 Medicina Ocupacional 0.42476 claro exceso 0.319927 cabo evaluaciones 0.29639 Cáncer usa datos 0.931444 contaminante ambiental 0.520538 contaminante sospechoso 0.478153	CLICK HERE
3603	National Cancer Institute	Html	en	The Biology of Cancer Health Disparities	Melanie Nix is a triple-negative breast cancer survivor.	colorectal cancer driver 0.435767 therapeutic drug development 0.379727 higher prostate cancer 0.449833 tumor suppressor 0.38934 tumor suppressor protein 0.381004 non-Ashkenazi Jewish women 0.407407 health statistics data 0.392619 poor prognosis 0.391856 early-stage colorectal cancer 0.438229 health disparities 0.477585 white men 0.458069 ethnic groups 0.593764 higher death rate 0.400926 5-year relative survival 0.383397 E-cadherin-mediated cell–cell adhesion 0.379902 prostate cancer cells 0.46714 triple-negative breast cancer 0.489042 Colorectal cancer incidence 0.443522 colorectal cancer 0.538585 health care services 0.381316 prostate cancer risk 0.477396 BRCA1 gene mutation 0.382642 biological factors 0.392157 tyrosine kinase activity 0.387964 colorectal cancers 0.435353	cancer health disparities 0.462858 poor prognosis subtype 0.390421 rare genetic variant 0.379533 tyrosine kinase 0.398457 African Americans 0.45451 triple-negative disease 0.382957 triple-negative breast cancers 0.481447 poorer breast cancer 0.423969 percent 0.4497 African American men 0.969659 African American patients 0.426534 ephrin type-A receptor 0.387324 premenopausal women 0.412405 prognosis molecular subtype 0.394461 germline BRCA1 mutations 0.399431 African American women 0.819019 breast cancer 0.507647 prostate cancer growth 0.440137 prostate cancer diagnosis 0.440132 prostate cancer 0.701352 non-Hispanic white women 0.414153 aggressive prostate cancer 0.430828 receptor tyrosine kinase 0.392354 higher nuclear levels 0.389163	CLICK HERE
14597	National Cancer Institute	Html	en	Common Cancer Myths and Misconceptions	The latest science-based information concerning some common misconceptions about cancer. Learn the facts to worry less and make good health decisions.	cancer treatment 0.293552 multiple family members 0.287169 different surgical tools 0.292574 best studies 0.351264 wrong ideas 0.256786 individual cancer patient 0.352232 Cancer patients 0.292909 artificial sweeteners 0.340098 Cancer Vaccines 0.299159 bladder cancer 0.291637 good prevention 0.259057 Cancer Risk 0.329552 tobacco smoke 0.287568 environmental factors 0.290117 Risk Factors 0.292696 magnetic energy 0.286101 complementary therapies 0.281474 person 0.354916 cancers 0.347867 Five-year survival rates 0.302006 common cancer myths 0.360301 Metastatic Cancer 0.322576 Annual Report 0.258223 NCI fact sheet 0.996571 United States 0.312478	excess weight gain 0.296228 cancer cells 0.333742 5-year survival rate 0.300282 Helicobacter pylori 0.298521 personal hair dye 0.285054 natural result 0.291706 Hereditary Cancer Syndromes 0.328419 cell phones 0.296722 scientific evidence 0.293613 No. Researchers 0.257042 needless worry 0.25947 old theories 0.256313 transplant-related cancer 0.304436 NCI fact sheets 0.326267 Botanicals/Herbal Products section 0.288672 No. 0.263456 Breast Cancer 0.289863 medicine products—including vitamins 0.287253 latest science-based information 0.32382 power lines 0.324548 thyroid cancers 0.300398 Certain popular ideas 0.304234 cancer 0.824886 information 0.40326	CLICK HERE
16448	National Cancer Institute	Html	en	Identifying Novel Drug Combinations to Overcome Treatment Resistance	A review of current research identifying and testing drug combination approaches that have the potential to overcome or delay resistance to cancer treatment.	cancer treatment 0.25347 cancer cell lines—a 0.280999 healthy cells 0.296062 novel drug combinations 0.308632 lung cancer 0.280527 chemotherapy resistance 0.310051 cancer drug resistance 0.46496 Kettering Cancer Center 0.280587 effective drug pairs 0.26607 clinical trials 0.313646 epigenetic alterations 0.2886 original drug 0.25941 molecular alterations 0.297668 myeloid cells 0.309525 ovarian cancer 0.356692 cisplatin resistance 0.289204 patients 0.50622 immune checkpoint inhibitors 0.342594 single tumor 0.262236 Nature Reviews Cancer 0.299509 potential drug combinations 0.282064 tumor—contain molecular alterations 0.269672 combination treatment approach 0.285984 multidrug resistance section 0.355811 drug resistance 0.805264	cancer drugs 0.296242 treatment 0.450602 Cancer Research UK 0.305072 ABC transporter inhibitors 0.39367 chemotherapy drugs 0.281313 breast cancer tumors 0.293816 cancer cells 0.926321 cancer cell lines 0.386565 so-called intrinsic resistance 0.362006 epigenetic alteration 0.261391 Dana-Farber Cancer Institute 0.280545 Dr. Gottesman 0.323556 DNA methylation 0.280984 Cancer Research 0.350827 ABC transporters 0.47073 Hospital Cancer Center 0.277242 epigenetic codes—molecular modifications 0.267446 cancer researchers 0.266263 inactivating T cells 0.270905 drugs 0.323984 ovarian cancer cell 0.296997 drug combinations 0.458324 tumor microenvironment 0.309626 lung cancer cell 0.275824	CLICK HERE